Introduction {#Sec1}
============

A major problem in the ageing nervous system is the progression of neuronal dysfunction, atrophy and cell death. One of the factors that have been implicated in this progressive neurodegeneration is the decrease in gonadal steroids with advancing age (Smith et al. [@CR70]). However, because steroids can be generated in the brain de novo from cholesterol (neurosteroids), the relation between sex steroids and age-related neuronal degeneration remains unclear (Schumacher et al. [@CR67]; Veiga et al. [@CR77]). Such information is important given the equivocal neuropsychological benefits and known side effects of systemic steroid hormone replacement for both men and women (for review see Pike et al. [@CR57]) and current research to develop strategies that augment neurosteroids as a potentially better neuroprotective treatment for the aged brain (Azcoitia et al. [@CR4]).

Cerebellar Purkinje cells provide a model with which to investigate the relative roles of circulating sex steroids and neurosteroids in age-related neuronal death. Purkinje cells are vulnerable neurons that die during ageing in both humans and rodents (Rogers et al. [@CR63]; Andersen et al. [@CR2]; Zhang et al. [@CR84]). As Purkinje cells age, there is initial synaptic dysfunction (Rogers et al. [@CR62]; Woodruff-Pak et al. [@CR81]) with associated motor and cognitive decline (Thouvarecq et al. [@CR74]; Woodruff-Pak [@CR80]) followed by dendritic atrophy (Quackenbush et al. [@CR61]; Zhang et al. [@CR83]) and finally cell death (Woodruff-Pak [@CR80]; Zhang et al. [@CR83]; Woodruff-Pak et al. [@CR81]). Purkinje cells are also targets of sex steroid action, expressing sex steroid receptors (Qin et al. [@CR59]) and being protected by oestrogens and progestins during development (Tsutsui [@CR75]; Biamonte et al. [@CR7]) and following injury (Jung et al. [@CR40]; Ardeshiri et al. [@CR3]; Kelley et al. [@CR45]). Moreover, oestrogens and progesterone promote Purkinje cell dendritic growth, spine formation and synaptic responses (Smith et al. [@CR69]; Sakamoto et al. [@CR65]; Sasahara et al. [@CR66]), parameters that are the first to decay during Purkinje cell ageing (Rogers et al. [@CR62]; Quackenbush et al. [@CR61]; Zhang et al. [@CR83], [@CR84]). Therefore, it may be proposed that Purkinje cells of all ages respond to sex steroids and that their progression through synaptic dysfunction, dendritic atrophy and death is secondary to the decline of sex steroid support during ageing. However, because Purkinje cells also synthesise neurosteroids (Tsutsui et al. [@CR76]), the impact of gonadal sex steroids on Purkinje cell death during ageing remains unknown.

A potential link between sex steroids and age-related Purkinje cell death arises from the heterozygous staggerer mouse (*Rora*^*+/sg*^), in which mutant RORα (retinoic acid receptor-related orphan receptor alpha) does not function (Hamilton et al. [@CR32]). In *Rora*^*+/sg*^ mice, Purkinje cells undergo the same age-related degenerative changes as normal cells, only at a much younger age (Caston et al. [@CR13]; Doulazmi et al. [@CR17]; Hadj-Sahraoui et al. [@CR31]; Caston et al. [@CR14], [@CR15]). Although it has been proposed that premature atrophy and death of *Rora*^*+/sg*^ Purkinje cells is intrinsic to the gene defect (Herrup and Mullen [@CR35]), there is a gender difference in their Purkinje cell loss that occurs earlier in males (Doulazmi et al. [@CR17]). This suggests that differences in sex steroidogenesis may underlie the premature degeneration of *Rora*^*+/sg*^ Purkinje cells. This premise is supported by the involvement of RORα in endocrine function; it regulates enzymes involved in sex steroid synthesis (Kang et al. [@CR42]; Wada et al. [@CR78]; Odawara et al. [@CR56]) and homozygous staggerer mice, which do not have RORα, have impaired reproductive capability (Feron and Baudoin [@CR21]; Guastavino and Larsson [@CR30]).

To test the hypothesis that gonadal steroids and neurosteroids are involved in age-related Purkinje cell death, we analysed Purkinje cell numbers and related them to plasma sex steroid and cerebellar neurosteroid concentrations during normal ageing (wild-type mice, WT). We then validated our theory experimentally: measuring sex steroids in a mouse model in which Purkinje cells are known to age prematurely (*Rora*^*+/sg*^ mice) and finally evaluating the role of steroids by examining the time-course of cell death following long-term sex steroid insufficiency post-gonadectomy. Our data reveal that circulating sex steroids fall in advance of or in parallel with Purkinje cell death during both normal and precocious ageing and that Purkinje cell death is advanced when there is sex steroid insufficiency. While cerebellar neurosteroids do not decrease with age they are profoundly reduced in male *Rora*^*+/sg*^ cerebella, which may enhance and/or explain the vulnerability of *Rora*^*+/sg*^ Purkinje cells in males. These data suggest that circulating sex steroids, rather than local neurosteroids, play an important neuroprotective role in the ageing cerebellum, which has important implications for treatment strategies of age-related neurodegenerative phenomena.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

Heterozygote staggerer (*Rora*^*+/sg*^) and WT mice were bred from heterozygous C57Bl/6 (*Rora*^*+/sg*^) pairs in our colony at the IFR 83 Biologie Integrative (Paris, France). Intact male and female WT and *Rora*^*+/sg*^ and gonadectomised WT mice were used for the measurements of Purkinje cell numbers and steroid concentrations at 3, 9, 13, 18 and 24 months of age. Females were randomly cycled. All efforts were made to minimise the number of animals used. Animals had access to food and water ad libitum and were housed under controlled temperature (24 ± 2°C) and a 14/10-h light/dark cycle. All animal procedures were performed under the guidelines established by 'le Comité National d'Ethique pour les Sciences de la Vie et de la Santé' and the European Communities Council Directive of November 24, 1986 (86/609/EEC).

Genotype analysis {#Sec4}
-----------------

Genomic DNA was extracted from tail biopsies as previously described (Gautheron et al. [@CR28]). Briefly, tissue was digested overnight at 55°C with proteinase K (Qiagen, Courtaboeuf, France) in TSE buffer containing in millimolar: 25 Tris--HCl pH 8.0, 75 NaCl, 25 EDTA pH 8.0 and SDS 1% (Sigma--Aldrich, Saint Quentin, France). DNA fragments were precipitated with isopropanol and washed with 70% ethanol prior to being dissolved in 100 μl of distilled water. DNA was amplified in two sets of reactions, one for each allele by PCR. The staggerer allele primers were: 5′-CGTTTGGCAAACTCCACC-3′ and 5′-GATTGAAAGCTGACTCGTTCC-3′. The WT allele primers were: 5′-TCTCCCTTCTCAGTCCTGACA-3′ and 5′-TATATTCCACCACACGGCAA-3′. The amplified fragments (318 bp Rora^+^ and 450 bp Rora^sg^) were detected by electrophoresis on a 2% agarose gel.

Gonadectomy and hormone replacement therapy {#Sec5}
-------------------------------------------

WT animals were bilaterally gonadectomised at 4 weeks of age under avertin anaesthesia (0.024 cc/g i.p.) and kept until 9, 13, 18 or 24 months, when blood was collected for sex steroid analysis and brains dissected for cell counts. All gonadectomised mice had steroids levels below detection limits.

Twenty-four hours after gonadectomy, animals received subcutaneous 90-day time-release hormone pellets (Innovative Research of America, FL. USA) releasing either 17β-estradiol (1,3,5-estratriene-3,17β-diol; 8.0 μg/day), progesterone (4-pregnene-3,20-dione, 0.38 mg/day) or vehicle. In addition, gonadectomised males were treated with dihydrotestosterone (5α-androstan-17β-ol-3-one, 0.14 mg/day) which cannot be converted to 17β-estradiol by aromatase. Hormone pellets were replaced under short isoflurane anaesthesia (3.5% isoflurane; 0.5% O~2~), four times over 1 year of treatment. Blood was collected every 3 months early in the light cycle (2--3 h after lights-on) to measure steroid concentrations by radioimmunoassay (RIA; Diagnostic Systems Laboratories, Inc., USA).

Body weight of different experimental groups was monitored on a regular basis. Initial group sizes of intact and castrated mice ranged from five to ten but were reduced to only two to five mice at 18 and 24 months due to a high incidence of late onset mortality. In the hormone replacement therapy experiment, initial group sizes ranged from five to eight animals.

Blood and brain collection for analysis of steroid levels {#Sec6}
---------------------------------------------------------

Blood samples were collected 2--3 h after lights-on, centrifuged at 3,000×g for 10 min at 4°C, and the plasma stored at −80°C until subsequent analysis. For brain steroids, animals were sacrificed by rapid cervical dislocation at 3, 9 and 13 months of age. The cerebellum was quickly removed on ice and stored at −80°C until steroid analysis

Measurement of steroid concentrations {#Sec7}
-------------------------------------

Steroid analysis was carried out on individual plasma/cerebellar samples according to a previously described method (Liere et al. [@CR50]; Weill-Engerer et al. [@CR79]; Liere et al. [@CR51]).

Briefly, 60--68-mg cerebellum and 150--300-μl plasma were used. Steroids were extracted from each sample with ten volumes of methanol together with the appropriate internal standards (Steraloids) added for steroid quantification: in plasma samples, ^2^H~5~-testosterone (2 ng) for testosterone; ^2^H~5~-17β-estradiol (2 ng) for 17β-estradiol and 19-nor-progesterone (2 ng) for progesterone; in cerebellar samples, 5β-androstane-3β-ol-17-one (1 ng) for pregnenolone and 5α-pregnane-3α-ol-20-one (allopregnanolone), and ^2^H~6~-5α-pregnane-3,20-dione, ^2^H~6~-5α dihydroprogesterone (2 ng) for 5α-dihydroprogesterone. Pregnenolone, progesterone and allopregnanolone were kind gifts from Roussel-Uclaf (Romainville, France), 5α-dihydroprogesterone, 5β-androstane-3β-ol-17-one and estradiol were purchased from Sigma. The unconjugated steroids were purified and isolated by solid phase extraction (SPE) on C18 silica minicolumns (International Sorbent technology, Mid Glamorgan, UK) with 5 ml MeOH/H~2~O (90/10, *v*/*v*) with the recycling procedure (Liere et al. [@CR51]). They were filtered and submitted to high-performance liquid chromatography (HPLC) coupled to a 202 model Gilson fraction collector. HPLC was achieved with a Lichrosorb Diol column (25 cm × 4.6 mm, 5 μm) and the solvent system consisted of hexane and mixture A (90:10, *v*/*v*), the latter composed of hexane-isopropanol (85:15, *v*/*v*). The elution was performed at a flow rate of 1 ml/min at 30°C. Fraction I containing 5α-dihydroprogesterone and ^2^H~6~-5α-dihydroprogesterone was collected between 3 and 11 min. Fraction II containing pregnenolone, progesterone, testosterone and 17β-estradiol and corresponding internal standards was collected from 10 to 30 min. The fraction II was derivatized with heptafluorobutyric anhydride (Pierce Chemical CA., Rockford, IL, USA), and the fraction I with N-methyl-N-trimethylsilyl-trifluoroacetamide/ammonium iodure/dithioerythritol, before identification and quantification by gas chromatography--mass spectrometry (GC--MS). GC injection was carried out in the splitless mode with a GC 8000 Top gas chromatograph (Carlo Erba) and the oven temperature was ramped up from 50°C to 330°C at 20°C/min. The mass spectrometer (model 150, Finnigan Automass, Argenteuil, France) was operated in the electron impact mode with ionisation energy of 70 eV in single ion monitoring mode. Identification of derivatized steroids was performed according to the GC retention time and ratio between the signals of two diagnostic ions. Quantification was carried out according to the major diagnostic ion (quantification ion). Each GC--MS measurement of individual plasma or brain sample was made in duplicate. The detection limits for plasma progesterone, testosterone and 17β-estradiol were respectively 0.01, 0.03 and 0.01 ng/ml. The detection limits for brain pregnenolone, progesterone, 5α-dihydroprogesterone and allopregnanolone respectively 0.80, 0.10, 0.10 and 0.20 ng/g.

Histology and Purkinje cell quantitation {#Sec8}
----------------------------------------

Under deep anaesthesia with 3.5% chloral-hydrate, mice were transcardially perfused with physiological saline and 4% paraformaldehyde in 0.1 M sodium phosphate-buffered saline (pH 7.4). Brains were dissected, post-fixed in 4% paraformaldehyde at 4°C overnight, then dehydrated, cleared and embedded in paraffin. Serial sagittal brain sections of 8 μm were stained with cresyl violet Nissl stain, which allows easy identification of the soma and nucleus of all Purkinje cells (Frederic et al. [@CR23]).

Purkinje cells were counted on a Leica microscope (Leica Paris, France) in male and female mice aged 3, 9, 13, 18 and 24 months. Counts were made blind and verified by a second investigator. Purkinje cell profiles were determined in every 40th section of the whole cerebellum as previously described (Doulazmi et al. [@CR17]). In each parasagittal section, the Purkinje cell layer was examined using an ×100 objective (×1000 total magnification) and every Purkinje cell with a visible nucleus was counted. To estimate the total number of Purkinje cells in each animal, profile counts were multiplied by 40 and corrected by the Hendry correction factor (Hendry [@CR34]). This method provides similar Purkinje cell numerical estimates as other stereological techniques (Zanjani et al. [@CR26]; Fan et al. [@CR19]; Zanjani et al. [@CR82]) and permits direct comparison with previously published Purkinje cell counts of this mutant.

Statistical analysis {#Sec9}
--------------------

### Steroid concentrations {#Sec10}

In order to have a normal distribution of sex steroids concentrations, we logged the data and verified normality by the Kolmogorov--Smirnov Goodness-of-Fit test. In case of a log-normal distribution, the differences in testosterone, 17β-estradiol and progesterone concentrations were assessed by a two-way (genotype, age) analysis of variance (ANOVA) with post hoc comparisons by the Newman--Keuls test. Since progesterone concentrations in males were not normally distributed after log-transformation, we applied non parametric ANOVA (Kruskal--Wallis with Mann--Whitney post hoc tests). We used the Spearman\'s rank correlation test to study the correlation between log plasma steroid concentrations and Purkinje cell number. Data are presented as the mean ± SEM. Significance was defined at *P* ≤ 0.05.

### Cell counts {#Sec11}

The difference between mean Purkinje cell numbers during ageing was assessed by 2- or 3-way analysis of variance (ANOVA) with post-hoc Newman--Keuls test. Following castration and hormone treatment Purkinje cell numbers were compared by the Kruskal--Wallis test. Data are presented as the mean ± SEM. Significance was defined at *P* ≤ 0.05.

Results {#Sec12}
=======

Circulating sex steroids decrease with age in advance of Purkinje cell death {#Sec13}
----------------------------------------------------------------------------

It is known that female mice have fewer Purkinje cells than males and that these neurons begin to die from 18 months in WT mice and much earlier in *Rora*^*+/sg*^ mice (Doulazmi et al. [@CR17]). To test the potential link between Purkinje cell death and circulating sex steroids, we measured plasma sex steroids between 3 and 24 months and correlated them with Purkinje cell numbers from the same animals. We analysed four to eight animals at each of five-age points for both genders in both genotypes.

We confirmed the gender difference in WT Purkinje cell numbers (Doulazmi et al. [@CR17]), with WT males having 7% more Purkinje cells than females (*F*~1,62~ = 17, *P* \< 0.0001; Fig. [1a and a](#Fig1){ref-type="fig"}\'), and the loss of Purkinje cells from 18 months in WTs and much earlier (*F*~1,118~ = 145, *P* \< 0.0001) in *Rora*^*+/sg*^ mice (Fig. [2](#Fig2){ref-type="fig"}; Doulazmi et al. [@CR17]). Because Purkinje cell death begins earlier in *Rora*^*+/sg*^ males (Fig. [1a and a](#Fig1){ref-type="fig"}\'; Doulazmi et al. [@CR17]), we observed that from 9 months of age *Rora*^*+/sg*^ males and females had the same number of Purkinje cells (compare Fig. [1a](#Fig1){ref-type="fig"} vs. a\', Fig. [3](#Fig3){ref-type="fig"}). Fig. 1Purkinje cell number and circulating sex steroids decrease with age. Evolution of Purkinje cell numbers (**a** and **a**\') and circulating sex steroid concentrations 17β-estradiol (**b** and **b**\'), progesterone (**c** and **c**\') and testosterone (**d**) in wild-type (*WT*) and heterozygous staggerer (*Rora*^*+/sg*^) males (*left panels*) and females (*right panels*) from 3 to 24 months of age. Values are represented as mean ± S.E.M; *n* = 4--8. The ages when rapid Purkinje cell death commences are indicated by *vertical dashed* (*WT*) or *dotted* (*Rora*^*+/sg*^) lines. Significant differences WT vs. *Rora*^*+/sg*^: *single asterisk P* \< 0.05; *double asterisk P* \< 0.01; *triple asterisk P* \< 0.001. Significant differences within genotypes: *single number sign P* \< 0.05; double number sign *P* \< 0.01; *triple number sign P* \< 0.001Fig. 2Fewer Purkinje cells in the aged *Rora*^*+/sg*^ than WT cerebellum. Micrographs of cerebellum stained with cresyl violet showing the Purkinje cell layer of WT (**a**) and *Rora*^*+/sg*^ (**b**) cerebella at 18 months of age. The density of the Purkinje cells (*single asterisk*) is less in the *Rora*^*+/sg*^ tissue. *Bar* = 50 μmFig. 3Hormone deficiency advances Purkinje cell loss. Mean (± S.E.M) number of Purkinje cells (*PC*) of intact and gonadectomized (*GDX*) WT and *Rora*^*+/sg*^ mice from 3 to 24 months. In WT mice, PC death begins earlier in gonadectomised (*GDX*) than intact mice. Also GDX removes the sexual dimorphism of PC numbers (Litteria [@CR53]) so that GDX males and females have the same numbers of PCs. In *Rora*^*+/sg*^ mice in association with their endocrine deficiency there is also no sexual dimorphism in the number of *Rora*^*+/sg*^ PCs, which have already begun to die by 3 months of age and whose death accelerates from 9 months of age. ![](11357_2010_9203_Figa_HTML.gif){#d28e966} = range of PC number in males at 1 month (Doulazmi et al. [@CR17]). Significant differences intact vs. GDX: *single asterisk P* \< 0.05. Significant differences WT male vs. female: *section sign P* \< 0.0001

Concerning sex steroids, in mice of both genotypes and genders plasma concentrations decreased with age (17β-estradiol *F*~4,85~ = 5, *P* \< 0.001; progesterone *F*~4,85~ = 20, *P* \< 0.0001; testosterone *F*~4,85~ = 2.6, *P* \< 0.05). There was also an effect of genotype, with plasma concentrations being lower in *Rora*^*+/sg*^ animals (17β-estradiol, *F*~1,85~ = 16, *P* \< 0.0001; progesterone, *F*~1,85~ = 17, *P* \< 0.0001; testosterone, *F*~1,85~ = 12.6, *P* \< 0.001).

Additional analysis revealed that in WT mice progesterone (*P* \< 0.01; Fig. [1c](#Fig1){ref-type="fig"}) and 17β-estradiol (*P* \< 0.05; Fig [1b](#Fig1){ref-type="fig"}) decreased in males from around 9 months, i.e. before Purkinje cell death (Fig. [1a](#Fig1){ref-type="fig"}). Also, testosterone fell from 18 months (*P* \< 0.05) in parallel with Purkinje cell loss (Fig. [1d](#Fig1){ref-type="fig"} vs. a). In contrast, in WT females changes in plasma sex steroids with age were less evident consistent with our use of randomly cycled mice, in which large hormonal variations due to the estrus cycle will mask smaller changes with age (Nelson et al. [@CR55]). However, progesterone decreased from 13 months (*P* \< 0.01; Fig. [1c](#Fig1){ref-type="fig"}\'), while 17β-estradiol did not show clear variance with age (Fig. [1b](#Fig1){ref-type="fig"}\') and testosterone was too low to detect any changes.

Correspondingly in *Rora*^*+/sg*^ mice, plasma sex steroids also decreased either before or in parallel to the acceleration in Purkinje cell death at 9 months of age (Fig. [1](#Fig1){ref-type="fig"}). In males, progesterone and 17β-estradiol were reduced from 3 months (*P* \< 0.05 each; Fig. [1b and c](#Fig1){ref-type="fig"}) so that they were less than WT (*P* \< 0.001, *P* \< 0.05, respectively; Fig. [1b, c](#Fig1){ref-type="fig"}). Also, testosterone levels fell from 9 months, the time when Purkinje cell death accelerates (Fig. [1a](#Fig1){ref-type="fig"} vs 1d). In female *Rora*^*+/sg*^ mice, progesterone decreased with age (*P* \< 0.01 Fig. [1c](#Fig1){ref-type="fig"}\'), 17β-estradiol was less than in WT (*P* \< 0.01) even before Purkinje cells loss (Fig. [1a](#Fig1){ref-type="fig"}\' vs 1b\'), and testosterone was almost undetectable.

In addition, these changes in plasma sex steroid concentrations correlated with Purkinje cell numbers of the same animals. Specifically, in males Purkinje cell numbers correlated directly with plasma 17β-estradiol, progesterone and testosterone concentration in both WT and *Rora*^*+/sg*^ mice (17β-estradiol, Spearman Rho = 0.5, *P* \< 0.01; progesterone, Rho = 0.63, *P* \< 0.01; testosterone, Rho = 0.46, *P* \< 0.05). In females, Purkinje cell numbers correlated with 17β-estradiol (Spearman Rho = 0.36, *P* \< 0.05) but not with progesterone concentrations, possibly because we used randomly cycled females.

In summary, in WT and *Rora*^*+/sg*^ animals circulating 17β-estradiol and progesterone were reduced in advance of Purkinje cell death and, in males, testosterone fell in parallel with cell loss.

Long-term hormone deficiency advances Purkinje cell death in ageing mice {#Sec14}
------------------------------------------------------------------------

Since circulating sex steroids appeared to decrease in advance of Purkinje cell death and were reduced in *Rora*^*+/sg*^ mice even at 3 months, we tested whether hormone deficiency precipitates Purkinje cell death during normal ageing. To do this, we reproduced the hormone deficient *Rora*^*+/sg*^ state by gonadectomy of WT mice and counted their Purkinje cells between 9 and 24 months.

Long-term gonadectomy altered Purkinje cell survival. Consistent with absent circulating sex steroids (see [Gonadectomy and hormone replacement therapy](#Sec5){ref-type="sec"} in [Materials and methods](#Sec2){ref-type="sec"} section) developmental sexually dimorphic changes in neuronal survival did not take place (Litteria [@CR53]), thus gonadectomised mice of both genders had the same number of Purkinje cells. Also gonadectomy advanced Purkinje cell loss, with both genders steadily losing Purkinje cells from 9 months of age (*F*~3,79~ = 11 *P* \< 0.0001; Fig. [3](#Fig3){ref-type="fig"}). Thus, because Purkinje cells do not start to die in intact WT mice until 18 months, gonadectomised WT males had significantly fewer Purkinje cells than intact males at 13 (−9%) and 18 (−18%) months (*P* \< 0.05, Fig. [3](#Fig3){ref-type="fig"}). However in gonadectomised females, the advanced Purkinje cell death (9 vs. 18 months; *P* \< 0.05), commenced from the number of Purkinje cells usually found in males, so that overall the number of Purkinje cells did not become significantly less than in intact females (Fig. [3](#Fig3){ref-type="fig"}).

To explore the relation of individual sex steroids to the advanced Purkinje cell loss in gonadectomised animals, we tested the effect of individual hormone replacement therapy for 12 months to normalise circulating sex steroids. Plasma 17β-estradiol, progesterone and dihydrotestosterone were monitored every 3 months and were in the physiological range (data not shown). However for both genders, at 13 months of age there were no apparent differences in Purkinje cell number between gonadectomised mice with or without replacement of individual hormones, 17β-estradiol, progesterone or dihydrotestosterone for 1 year (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4No effect of hormone treatment on Purkinje cell death. Mean (± S.E.M) number of Purkinje cells of 13-month old intact or gonadectomized (GDX) WT animals treated for 12 months with placebo (*GDX-oil*), 17β-estradiol (*+E2*), progesterone (*+Prog*) or dihydrotestosterone (*DHT*). GDX WT males had fewer PCs than intact WT. There were no significant differences in PC number between the different hormone treatment groups of gonadectomized males and females. Significant differences intact vs. GDX: *single asterisk P* \< 0.05

In summary, in ageing WT animals Purkinje cell death is advanced after long-term deficiency of sex steroids, although replacement of individual hormones could not reverse this premature cell loss.

Cerebellar neurosteroid concentrations do not change with age {#Sec15}
-------------------------------------------------------------

Our data indicate a relation between circulating sex steroids and Purkinje cell survival, with neuronal loss being preceded by falling 17β-estradiol and progesterone and precipitated by long-term hormone deficiency. However there is a delay between falling steroid levels and Purkinje cell loss, which may be due to the neuroprotective properties of Purkinje cell-synthesised neurosteroids. Therefore, we measured cerebellar neurosteroids before and during Purkinje cell death in WT and *Rora*^*+/sg*^ mice (*n* = 6 for each gender and genotype).

In WT animals, cerebellar neurosteroids did not vary between 3 and 13 months of age (Fig. [5](#Fig5){ref-type="fig"}). However, at all ages there was a gender difference with lower neurosteroid (pregnenolone, 5α-dihydroprogesterone and allopregnanolone) concentrations in females compared to males (*F*~1,28~ = 36 *P* \< 0.0001; *F*~1,29~ = 26 *P* \< 0.0001; *F*~1,29~ = 29 *P* \< 0.0001, respectively; compare Fig. [5](#Fig5){ref-type="fig"} left and right columns). These data parallel the stable number of Purkinje cells between 3 and 13 months and smaller number of Purkinje cells in the female cerebellum (Figs. [1](#Fig1){ref-type="fig"} and [3](#Fig3){ref-type="fig"}; Doulazmi et al. [@CR17]). Fig. 5Cerebellar neurosteroids do not decrease with age. Concentrations (mean ± S.E.M) of cerebellar neurosteroids, pregnenolone, allopregnanolone and 5α-dihydroprogesterone in 3--13-month-old wild-type (WT) and *Rora*^*+/sg*^ mice (*n* = 6 per group). In WT, these neurosteroid concentrations are higher in males than females and in RORα^+/sg^ the sexual dimorphism disappears, with reduced neurosteroid concentrations in males. Significant differences WT vs. *Rora*^*+/sg*^: *single asterisk P* \< 0.05; *triple asterisk P* \< 0.001. Significant differences WT male vs. female: *section sign P* \< 0.05

In addition, in *Rora*^*+/sg*^ mutant mice cerebellar steroids also did not change between 3 and 13 months (Fig. [5](#Fig5){ref-type="fig"}). Furthermore in contrast to WT, cerebellar steroid concentrations were the same in male and female *Rora*^*+/sg*^ mice (Fig. [5](#Fig5){ref-type="fig"}, compare left and right columns). As a consequence, compared to WT cerebellar neurosteroids were reduced in *Rora*^*+/sg*^ males (pregnenolone *F*~1,29~ = 13 *P* \< 0.001, 5α-dihydroprogesterone *F*~1,29~ = 4 *P* \< 0.05, allopregnanolone *F*~1,29~ = 15 *P* \< 0.001). Thus in contrast to WT, in *Rora*^*+/sg*^ mice there is no correlation between stable neurosteroid concentrations and falling numbers of Purkinje cells.

In summary, cerebellar neurosteroid concentrations do not change between 3 and 13 months, and, although they are reduced in *Rora*^*+/sg*^ males, their profile does not accord with ongoing Purkinje cell loss in the *Rora*^*+/sg*^ cerebellum.

Discussion {#Sec16}
==========

In this study, we examined the relation between age-related neuronal degeneration and sex steroids during normal ageing, and in *Rora*^*+/sg*^ and gonadectomised experimental models. Our data reveal a statistical correlation between age, Purkinje cell loss and falling levels of circulating sex steroids, and a deficit in both circulating sex steroids and cerebellar neurosteroids in *Rora*^*+/sg*^ mice. From these data, we propose that during ageing Purkinje cell death is sex steroid dependent and that the precocious neuronal loss in *Rora*^*+/sg*^ animals results from premature sex steroid deficiency.

Death of ageing Purkinje cells is related to decreased sex steroids {#Sec17}
-------------------------------------------------------------------

From the results from this study, we hypothesise that a deficiency of circulating sex steroids causes age-related Purkinje cell death. Our study provides three independent lines of evidence to support this hypothesis. First, in normal ageing animals circulating steroids fall just in advance of, or in parallel to, Purkinje cell death. Importantly, throughout the ageing process the number of surviving Purkinje cells directly correlates with plasma sex steroid concentrations (17β-estradiol, progesterone and testosterone in males and 17β-estradiol in females). Second, when circulating sex steroids are removed prematurely by gonadectomy, the onset of Purkinje cell death is advanced from 18 to 9 months. This finding is consistent with the known neuroprotective function of sex steroids in development (Tsutsui [@CR75]; Biamonte et al. [@CR7]), injury (De Nicola et al. [@CR16]; Fargo et al. [@CR20]; Herson et al. [@CR36]; Suzuki et al. [@CR72]) and neurodegenerative disease (Bourque et al. [@CR11]; Garcia-Segura and Balthazart [@CR25]; Gold and Voskuhl [@CR29]) and adds that they have a similar neuroprotective role during normal ageing. Third, when Purkinje cell death is advanced in a genetic model of premature ageing (*Rora*^*+/sg*^ mice; Jarvis et al. [@CR39]; Boukhtouche et al. [@CR9]) we identify, for the first time, that circulating sex steroid concentrations are prematurely reduced and that this sex steroid loss precedes, or is concurrent with, Purkinje cell death. Thus plasma sex steroid concentrations and Purkinje cell numbers remain concordant during ageing in both normal WT and *Rora*^*+/sg*^ mutant mice; data which concur with sex steroid deficiency in disorders involving neuronal loss, such as Alzheimer\'s disease (Schumacher et al. [@CR67]; Pike et al. [@CR57]). Although the temporal correlation of Purkinje cell loss and falling steroid concentrations during ageing could be just circumstantial, our data showing similar but premature Purkinje cell loss in two different models of endocrine deficiency (gonadectomy or *Rora*^*+/sg*^ mutation) implies a causal relationship.

We further probed the relation between the requirement for circulating sex steroids and survival of ageing Purkinje cells by testing whether hormone replacement treatment prevented premature Purkinje neuron loss following gonadectomy. Although our treatment did not improve Purkinje cell survival, we only gave monotherapy and mice normally have circulating levels of all three hormones: 17β-estradiol, progesterone and testosterone. Indeed, consistent with our data, it has recently been shown that dihydrotestosterone replacement in orchidectomised rats does not increase brain steroid concentrations (Pluchino et al. [@CR58]), and that effective neuroprotection requires the combination of exogenous oestrogens and progestins (Smith et al. [@CR69]; Kipp and Beyer [@CR46]; Lenzi et al. [@CR49]). Therefore the failure of individual sex steroids to prevent premature Purkinje cell death post-gonadectomy, further supports the hypothesis that survival of ageing Purkinje cells requires the integrity of the whole circulating sex steroid profile.

Cerebellar neurosteroids do not decrease with age {#Sec18}
-------------------------------------------------

Although our data reveal a clear relation between age-related Purkinje cell death and circulating sex steroids, Purkinje cells also synthesise neurosteroids (Baulieu [@CR5]; Tsutsui et al. [@CR76]), for which changes during normal ageing remain ill-defined (Schumacher et al. [@CR67]; Rosario et al. [@CR64]) and which could explain the delay between falling plasma steroids and age-related Purkinje cell death.

We show that cerebellar neurosteroids do not change between young adult (3 months) and aged (13 months) animals. We also show that cerebellar neurosteroid synthesis is sexually dimorphic in WTs (being higher in males) but not in *Rora*^*+/sg*^, so that *Rora*^*+/sg*^ males have reduced cerebellar neurosteroids compared to age-matched controls, even as young adults (i.e. at 3 months). Given that progestins are neuroprotective (Garcia-Segura and Balthazart [@CR25]; Herson et al. [@CR36]), the expression profile we observed is consistent with the stable, sexually dimorphic number of WT Purkinje cells (this study; Doulazmi et al. [@CR17]) as well as compromised survival of young adult male *Rora*^*+/sg*^ Purkinje cells. However, we did not observe a significant decrease in neurosteroid concentrations in *Rora*^*+/sg*^ females, despite their accelerating age-related Purkinje cell loss from 9 months. This is consistent with human studies showing age-related decrease of brain sex steroids in males but not in females (Rosario et al. [@CR64]) and the sexually dimorphic expression of key neurosteroidogenic enzymes, such as StAR, P450scc and aromatase (Lavaque et al. [@CR48]). Taken together, our data do not demonstrate a clear role for cerebellar neurosteroids in the survival or death of ageing Purkinje cells.

Death of ageing Purkinje cells: interactions of sex steroids and RORα {#Sec19}
---------------------------------------------------------------------

Although sex steroids are protective to immature Purkinje cells (Tsutsui [@CR75]; Biamonte et al. [@CR7]), our data from hormone deficient mice (*Rora*^*+/sg*^ and gonadectomised WT) now add that sex steroids also have an important neuroprotective role during normal ageing. In these *Rora*^*+/sg*^ and gonadectomised WT animals the number of Purkinje cells only declined from 9 months of age (Fig. [3](#Fig3){ref-type="fig"}); i.e. hormone deprived Purkinje cells continue to survive until the animals are aged (i.e. to 9 months), thus revealing that vulnerability to sex steroid deficiency is a phenomenon of the ageing Purkinje cell rather than young adult neurons which survive regardless.

A re-development of hormone dependency as Purkinje cells age is entirely consistent with physiological changes which take place during ageing and the functions of sex steroids. As the brain ages, among other alterations that may adversely affect neuronal survival, neurotrophic factor synthesis/signalling decreases (Bishop et al. [@CR8]; Katoh-Semba et al. [@CR43]; Sonntag et al. [@CR71]; Tapia-Arancibia et al. [@CR73]; Luppi et al. [@CR54]) and oxidative stress and free radicals accumulate (Hanawalt [@CR33]). Importantly for age-related Purkinje cell death, sex steroids regulate both these processes. First, sex steroids promote the expression and signalling of brain-derived neurotrophic factor (BDNF; Begliuomini et al. [@CR6]; Kaur et al. [@CR44]) and insulin-like growth factor-1 (IGF-1; Garcia-Segura et al. [@CR27]; Alonso et al. [@CR1]; Luppi et al. [@CR54]), both of which are survival factors for Purkinje cells (Larkfors et al. [@CR47]; Lindholm et al. [@CR52]; Fukudome et al. [@CR24]). Indeed the neuroprotective action of oestrogen and progesterone are mediated through BDNF and IGF-1 receptor signalling and their downstream pathways through MAP kinase and phosphatidylinositol-3 kinase (Garcia-Segura et al. [@CR27]; Kaur et al. [@CR44]; Alonso et al. [@CR1]). Second, sex steroids protect against oxidative stress and free radicals (Dubal et al. [@CR18]; Ardeshiri et al. [@CR3]; Kelley et al. [@CR45]; Jung et al. [@CR41]), processes to which Purkinje cells are known to be sensitive (Horn and Schlote [@CR37]; Brasko et al. [@CR12]; Fonnum and Lock [@CR22]). Therefore in WT mice, falling circulating sex steroid concentrations during ageing (this study; Smith et al. [@CR70]) and long-term hormone insufficiency post-gonadectomy, can adversely affect Purkinje cells by simultaneously reducing two key survival factors and protection against oxidative stress; a combination which only becomes critical as free radicals and oxidative stress accumulate with age (Hanawalt [@CR33]).

This hypothesis linking the decrease in circulating sex steroids with death of ageing Purkinje cells is reinforced in *Rora*^*+/sg*^ mice. In these mice, we show that circulating sex steroids fall prematurely, consistent with the role of RORα regulating enzymes involved in steroidogenesis, e.g. 3ß-hydroxysteroid dehydrogenases (Kang et al. [@CR42]) and aromatase (Odawara et al. [@CR56]). In addition *Rora*^*+/sg*^ Purkinje cells, which are already intrinsically vulnerable due to their genetic defect (Herrup and Mullen [@CR35]) and gradually degenerate from 1 month of age (Doulazmi et al. [@CR17]), die early (as demonstrated by accelerated Purkinje cell loss in *Rora*^*+/sg*^ from 9 months). However, the fact that Purkinje cell loss was only gradual to 9 months confirms that Purkinje cell susceptibility to circulating sex steroid deficiency is a phenomenon of ageing; i.e. even though genetically vulnerable Purkinje cells gradually die, it is only after circulating sex steroids fail prematurely and Purkinje cells become aged that their death accelerates. Given that RORα itself promotes BDNF synthesis (Qiu et al. [@CR60]), IGF-1 signalling (Jaradat et al. [@CR38]) and anti-oxidant function (Boukhtouche et al. [@CR10]), Rorα haplo-insufficiency in the *Rora*^*+/sg*^ mouse renders their Purkinje cells more vulnerable to oxidative stress that accrues during ageing. This effect would be exacerbated by the premature loss of neurotrophic and anti-oxidant properties of sex steroids, initially endogenous neurosteroids (Sakamoto et al. [@CR65]; Sasahara et al. [@CR66]; Tsutsui [@CR75]) then circulating hormones. Since in WT animals RORα expression does not appear to vary with age (Sharman et al. [@CR68]), we propose that the difference in Purkinje cell number between *Rora*^*+/sg*^ and gonadectomised WT after 9 months of age reflects the added vulnerability induced by Rorα haplo-insufficiency on top of susceptibility of ageing Purkinje cells to sex steroid deficiency.

Conclusions {#Sec20}
===========

In conclusion, this study reveals that age-related cerebellar Purkinje cell neurodegeneration correlates with the decline in circulating sex steroids in both WT and *Rora*^*+/sg*^ mice. In contrast, cerebellar neurosteroids do not decrease with age, but are decreased in male *Rora*^*+/sg*^ which might cause or enhance the vulnerability of their mutant Purkinje cells. From these data, we hypothesise that during normal ageing, death of Purkinje cells can be delayed by the combination of circulating sex steroids or advanced by premature sex steroid loss, such may be induced by gonadal failure or Rorα haplo-insufficiency.
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